U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H23NO2.ClH
Molecular Weight 297.82
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHOHEPTAZINE HYDROCHLORIDE

SMILES

Cl.CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=XHRYXPJUXHWWJD-UHFFFAOYSA-N
InChI=1S/C16H23NO2.ClH/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16;/h4-6,8-9H,3,7,10-13H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H23NO2
Molecular Weight 261.3593
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Primary
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Doses

Doses

DosePopulationAdverse events​
100 mg 6 times / day multiple, oral
Recommended
Dose: 100 mg, 6 times / day
Route: oral
Route: multiple
Dose: 100 mg, 6 times / day
Sources: Page: p.416
unhealthy
n = 83
Health Status: unhealthy
Condition: Pain
Sex: F
Population Size: 83
Sources: Page: p.416
PubMed

PubMed

TitleDatePubMed
Analgesic effectiveness of orally administered ethoheptazine in man.
1957 Oct
Methods in evaluating ethoheptazine and ethoheptazine combined with aspirin.
1958 Apr 12
Clinical comparison of ethoheptazine and aspirin with other analgesic combinations.
1961 Mar
Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study.
1974 Sep
Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone.
1979
Determination of ethoheptazine in human post mortem material.
1983 Oct 14
Fixed drug eruption masquerading as herpes simplex labialis.
1984 Sep 29
Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain.
1987 Feb
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 08:53:13 GMT 2023
Edited
by admin
on Sat Dec 16 08:53:13 GMT 2023
Record UNII
8KYO8O8JNO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHOHEPTAZINE HYDROCHLORIDE
MI  
Common Name English
1H-AZEPINE-4-CARBOXYLIC ACID, HEXAHYDRO-1-METHYL-4-PHENYL-, ETHYL ESTER, HYDROCHLORIDE (1:1)
Systematic Name English
ETHOHEPTAZINE HYDROCHLORIDE [MI]
Common Name English
HEXAHYDRO-1-METHYL-4-PHENYL-1H-AZEPINE-4-CARBOXYLIC ACID ETHYL ESTER HYDROCHLORIDE
Systematic Name English
NSC-400484
Code English
Code System Code Type Description
EPA CompTox
DTXSID5048762
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY
PUBCHEM
23616254
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY
MERCK INDEX
m1138
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY Merck Index
CAS
5982-61-6
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY
FDA UNII
8KYO8O8JNO
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY
DRUG BANK
DBSALT002450
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY
NSC
400484
Created by admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
PRIMARY